Literature DB >> 30221248

Understanding the impact of neoadjuvant chemoradiation on health-related quality of life in esophageal cancer.

Tara R Semenkovich1, Bryan F Meyers1.   

Abstract

Entities:  

Year:  2018        PMID： 30221248      PMCID： PMC6135084          DOI： 10.21037/vats.2018.06.01

Source DB:  PubMed          Journal:  Video Assist Thorac Surg        ISSN： 2519-0792


× No keyword cloud information.
  7 in total

1.  Preoperative chemoradiotherapy for esophageal or junctional cancer.

Authors:  P van Hagen; M C C M Hulshof; J J B van Lanschot; E W Steyerberg; M I van Berge Henegouwen; B P L Wijnhoven; D J Richel; G A P Nieuwenhuijzen; G A P Hospers; J J Bonenkamp; M A Cuesta; R J B Blaisse; O R C Busch; F J W ten Kate; G-J Creemers; C J A Punt; J T M Plukker; H M W Verheul; E J Spillenaar Bilgen; H van Dekken; M J C van der Sangen; T Rozema; K Biermann; J C Beukema; A H M Piet; C M van Rij; J G Reinders; H W Tilanus; A van der Gaast
Journal:  N Engl J Med       Date:  2012-05-31       Impact factor: 91.245

Review 2.  The current status of neoadjuvant therapy for esophageal cancer.

Authors:  Daniel Lin; Lawrence Leichman
Journal:  Semin Thorac Cardiovasc Surg       Date:  2014-07-16

3.  Effect of Neoadjuvant Chemoradiotherapy on Health-Related Quality of Life in Esophageal or Junctional Cancer: Results From the Randomized CROSS Trial.

Authors:  Bo Jan Noordman; Mathilde G E Verdam; Sjoerd M Lagarde; Maarten C C M Hulshof; Pieter van Hagen; Mark I van Berge Henegouwen; Bas P L Wijnhoven; Hanneke W M van Laarhoven; Grard A P Nieuwenhuijzen; Geke A P Hospers; Johannes J Bonenkamp; Miguel A Cuesta; Reinoud J B Blaisse; Olivier R Busch; Fiebo J W Ten Kate; Geert-Jan M Creemers; Cornelis J A Punt; John Th M Plukker; Henk M W Verheul; Ernst J Spillenaar Bilgen; Herman van Dekken; Maurice J C van der Sangen; Tom Rozema; Katharina Biermann; Jannet C Beukema; Anna H M Piet; Caroline M van Rij; Janny G Reinders; Hugo W Tilanus; Ewout W Steyerberg; Ate van der Gaast; Mirjam A G Sprangers; J Jan B van Lanschot
Journal:  J Clin Oncol       Date:  2017-11-21       Impact factor: 44.544

4.  INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy.

Authors:  Bruce D Minsky; Thomas F Pajak; Robert J Ginsberg; Thomas M Pisansky; James Martenson; Ritsuko Komaki; Gordon Okawara; Seth A Rosenthal; David P Kelsen
Journal:  J Clin Oncol       Date:  2002-03-01       Impact factor: 44.544

Review 5.  Patient-Reported Outcomes in Thoracic Surgery.

Authors:  Onkar V Khullar; Felix G Fernandez
Journal:  Thorac Surg Clin       Date:  2017-05-22       Impact factor: 1.750

6.  Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.

Authors:  Joel Shapiro; J Jan B van Lanschot; Maarten C C M Hulshof; Pieter van Hagen; Mark I van Berge Henegouwen; Bas P L Wijnhoven; Hanneke W M van Laarhoven; Grard A P Nieuwenhuijzen; Geke A P Hospers; Johannes J Bonenkamp; Miguel A Cuesta; Reinoud J B Blaisse; Olivier R C Busch; Fiebo J W Ten Kate; Geert-Jan M Creemers; Cornelis J A Punt; John Th M Plukker; Henk M W Verheul; Ernst J Spillenaar Bilgen; Herman van Dekken; Maurice J C van der Sangen; Tom Rozema; Katharina Biermann; Jannet C Beukema; Anna H M Piet; Caroline M van Rij; Janny G Reinders; Hugo W Tilanus; Ewout W Steyerberg; Ate van der Gaast
Journal:  Lancet Oncol       Date:  2015-08-05       Impact factor: 41.316

7.  Complete pathologic response after neoadjuvant chemoradiotherapy for esophageal cancer is associated with enhanced survival.

Authors:  James M Donahue; Francis C Nichols; Zhuo Li; David A Schomas; Mark S Allen; Stephen D Cassivi; Aminah Jatoi; Robert C Miller; Dennis A Wigle; K Robert Shen; Claude Deschamps
Journal:  Ann Thorac Surg       Date:  2009-02       Impact factor: 4.330
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.